Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs.
about
Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID)Health-related quality of life in patients with primary immunodeficiency diseaseUpdate in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditionsThe European internet-based patient and research database for primary immunodeficiencies: results 2006-2008Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatmentSubcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease.II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies.Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.Early B cell defects.Subcutaneous immunoglobulin-g replacement therapy with preparations currently available in the United States for intravenous or intramuscular use: reasons and regimens.How I treat common variable immune deficiency.Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiencyIntravenous immunoglobulin: regulatory perspectives on use and supply.Current perspectives on common variable immunodeficiency (CVID).Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary Immunodeficiency.Primary immune deficiencies - principles of care.Immunoglobulin E in primary immunodeficiency diseases.Immunoglobulin therapy: history, indications, and routes of administration.Subcutaneous immunoglobulin in treating inflammatory neuromuscular disorders.Human normal immunoglobulin in the treatment of primary immunodeficiency diseases.Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency.Genetic analysis of patients with defects in early B-cell development.Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study.Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases.Common variable immunodeficiency: an updateC1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option.Clinical and immunological features of common variable immunodeficiency in ChinaImmunoglobulin replacement therapy in children.Does the route of immunoglobin replacement therapy impact quality of life and satisfaction in patients with primary immunodeficiency? Insights from the French cohort "Visages".Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.Common infusion-related reactions to subcutaneous immunoglobulin therapy: Managing patient expectationsEfficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.Pharmacoeconomics of immunoglobulins in primary immunodeficiency.Subcutaneous immunoglobulin: opportunities and outlook.TEC family kinases in health and disease--loss-of-function of BTK and ITK and the gain-of-function fusions ITK-SYK and BTK-SYK.Indications and safety of intravenous and subcutaneous immunoglobulin therapy.Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.Modern management of primary B-cell immunodeficiencies.
P2860
Q24681818-BFA0C7EB-3A42-4AC3-9062-4FD1927E8106Q26784167-3B6217FE-93D1-4EF3-A943-D7D30B3AB709Q28240370-60DBF709-31D0-4C0C-94F2-28984604F1DFQ28752166-2412DB87-D5C4-4C12-B9C2-F10C0E59775DQ33583520-E2B00FA3-6620-42DB-847F-38101A0D0048Q33635013-A70B2E97-97B3-4222-856E-AA295F104118Q33692418-A35A4F6C-2CA0-4886-AE22-095DA4AD213DQ33798442-8D3D8D02-9BB8-474E-9FCB-1E2E9CADDA69Q33848541-97CA2C4A-940E-4131-B78B-707A8FB39DFDQ33878939-BB5F640D-3D25-47BE-A3B7-89B500A78D61Q33997226-21A8F2FF-4744-4837-B0C4-5F91A6D77946Q34112793-B1F348DF-7C7C-4C57-AD13-A26F452E23AEQ34216781-DFD013C0-2E4D-4E91-982F-8FEE489C529CQ34255299-1968FE58-83CA-43C0-91E1-2BE92C23BCBAQ34627045-280BEE6D-88B8-4A65-958E-B6EBC8346D10Q34700023-598D9689-6F23-47D8-87E4-034B4D8A78A4Q34929232-F97118C6-DE0E-433D-B969-B58F7B4ECBB7Q35685969-33A2782D-D841-424D-88E5-80260C0E7582Q35780802-FED8DD9D-5255-49DB-87FD-8C6B1A735481Q35905557-B60E20FA-E0BB-4BCD-819E-31C611A6B0C1Q35959163-4F3C5D61-18C6-4A40-BFAF-B33E11368437Q36015046-DF1BFD10-19EB-47F8-9533-9A900D3C8BC1Q36094658-060B51A9-F05C-490F-ADA4-AA451B6E3222Q36196688-5681C304-0226-47F7-A169-C9D8107A2B53Q36633106-4DBC9F5E-E1A1-4154-B1DB-D2719D8697FEQ36687522-27F4D4CB-4A8A-431F-ADB3-3AFB77C2A6C8Q36816408-A13098F8-246F-42FD-AE9C-7EC0532AF795Q36979273-A760DFD6-887E-4B51-9D98-84A201D34C38Q37031111-0979E60B-9259-4355-A0A3-B45094F8F29BQ37125900-E9105FE5-E177-455C-9E81-38728E155FAEQ37246362-84351F4B-734D-4E32-9453-D0D38A68B114Q37405485-82F29BD4-4714-4AC3-8CA9-8F0DC7BC84F6Q37514512-F6F90D6D-2C56-4512-9140-B68674953EECQ37577898-620964C2-9CA8-4A32-B839-180F4A54E7F1Q37626132-535B5013-925B-4C09-B653-3CA9492FCFCFQ37868757-B90B18B4-D3A0-4F73-BE5A-B00447BBED81Q37877259-797915FB-4A6D-4FE9-9732-BE1C06EF3B59Q37890936-433A9C77-235F-46E3-A15C-0FFE5A51EEC5Q37929510-6409C4F8-094C-432A-84A4-BCE28146E903Q37962045-B855F13A-1730-47BE-982E-D883C223F40C
P2860
Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
Subcutaneous immunoglobulin re ...... eficiencies: safety and costs.
@en
Subcutaneous immunoglobulin re ...... eficiencies: safety and costs.
@nl
type
label
Subcutaneous immunoglobulin re ...... eficiencies: safety and costs.
@en
Subcutaneous immunoglobulin re ...... eficiencies: safety and costs.
@nl
prefLabel
Subcutaneous immunoglobulin re ...... eficiencies: safety and costs.
@en
Subcutaneous immunoglobulin re ...... eficiencies: safety and costs.
@nl
P2093
P1433
P1476
Subcutaneous immunoglobulin re ...... eficiencies: safety and costs.
@en
P2093
J Björkander
M B Jacobsen
R Gustafson
S S Frøland
V Andersen
P304
P356
10.1016/S0140-6736(95)90346-1
P407
P577
1995-02-01T00:00:00Z